PEG-MGF

What it is

PEG-MGF is sold as MGF with a chain of polyethylene glycol (PEG) attached, a process called pegylation¹⁶. MGF, short for mechano growth factor, is named after one of several forms of insulin-like growth factor 1 (IGF-1). The IGF-1 gene can be spliced (its pieces cut and rejoined) in different ways, giving forms that share the same mature hormone but end in different tails, called E domains²²²³. The form behind MGF is called IGF-1Ec in people and IGF-1Eb in rats and rabbits, and rabbit studies found that muscle makes more of it when stretched³²³²⁴. What is sold as MGF is not that whole protein but a lab-made copy of its tail: a 24-amino-acid peptide matching the E domain of the human form²¹²³. A 2010 review noted that no such free peptide had been found in cells, animal tissues or body fluids². Goldspink’s group reported in 2002 that the E-domain peptide made muscle precursor cells multiply, acting through a receptor other than IGF-1’s²⁵. Drug-company scientists who tried to repeat such cell results in 2014 found no apparent effect¹⁰. Sellers say the PEG chain makes the peptide last longer in the body⁶⁷, but we found no study that measured this, and a 2026 review lists no half-life for it¹.

Geoffrey Goldspink and colleagues reported in 1996 that stretched rabbit muscle makes more of an unusual form of IGF-1²¹²⁴. In 1999 his group at the Royal Free and University College Medical School in London proposed calling it mechano growth factor, or MGF³. The name later passed to the synthetic 24-amino-acid E-domain peptide²²¹. Anti-doping scientists described black-market MGF products in 2012²⁰. We found no source saying who first attached PEG to MGF, or when. Wells Pharmacy Network nominated PEG-MGF to FDA for use in compounding: the docket lists its nomination, with attachments titled ‘PEG-MGF Nomination Packet’, as received on 23 March 2021²⁶.

Benefits: what the research shows

We found no published study of PEG-MGF in people or animals. FDA says it ‘has not identified any human exposure data on drug products containing PEG-MGF administered via any route of administration’¹¹. A ClinicalTrials.gov search on 8 October 2026 for PEG-MGF, mechano growth factor or IGF-1Ec returned 501 records; none gave MGF or PEG-MGF to anyone, and two only measure the body’s own MGF³⁰. PubMed searches found no study that tested PEG-MGF itself and no trial that gave people any MGF peptide⁴⁵³¹. A 2026 medical review lists ‘No peer-reviewed human studies’ for PEG-MGF and warns that effects seen with natural IGF-1Ec or E-domain peptides ‘cannot be assumed to apply to PEG-conjugated constructs’¹. We therefore do not count studies of MGF without PEG as evidence for PEG-MGF. One mouse study delivered MGF from tiny rods of a PEG-based gel, but it did not attach PEG to the peptide²⁸. A 2013 mouse study used MGF differently, as a tag attached through PEG chains to nanoparticles of chitosan, a sugar-based material, to help carry a test RNA from the nose to the brain. It tracked where the RNA went and looked for tissue damage, not for any effect of MGF itself³². A 2017 first-in-human study of RO5046013, a pegylated form of the whole IGF-1 hormone, in 62 healthy volunteers tested a different molecule and does not count either³³. All other evidence concerns MGF peptides without PEG, in cells and animals, and it conflicts. Animal studies reported that MGF peptides helped transplanted human muscle precursor cells take hold in mice³⁴, improved healing of a bone gap in rabbits at the higher of two doses⁸, improved healing of injured rat tendons³⁵, protected brain cells in gerbils after a brief loss of blood flow to the brain³⁶, and preserved heart function after heart attacks in sheep and mice^9222829. In mice with bruised calf muscles and some immune cells (macrophages) removed, MGF injections reduced scarring but did not improve the regrowth of muscle fibers³⁷. In a 2014 study by drug-company scientists, MGF at up to 500 ng/ml did not make mouse or human muscle cells multiply, while IGF-1 did; in heart muscle cells, neither the natural peptide nor a stabilized version showed any activating effect¹⁰. An editorial on that study summed up the authors’ view that MGF ‘on its own, even when modified to enhance its half-life’, was inert, while noting that ‘the last word about MGF has not been written yet’³⁸.

Key human studies

No completed human studies were found.

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

Half-life

No measurement found in people or animals¹A 2026 medical review reports no half-life for PEG-MGF (‘t½ not reported’)¹. Sellers’ claims conflict: one says PEG extends the half-life ‘from minutes to hours’, another says PEG gives it ‘a half-life of several days’⁶⁷. We found no study that measured either. Anti-doping scientists found that an MGF variant without PEG, R23H, ‘has good stability’ in blood plasma in a test tube, without giving a half-life¹⁹.

Routes

• Injection under the skin (the route community sites list; we found no human or animal data for PEG-MGF)
• Injection into muscle (in forum reports compiled by a 2026 review; we found no human or animal data for PEG-MGF)
• Injection into muscle or the heart, or infusion from a pump implanted under the skin (MGF peptides without PEG, in animals only)

Every dose studied for PEG-MGF, with sources →

Legal status

United States

PEG-MGF is not approved by FDA for any use. A search of FDA’s approved-drug database (Drugs@FDA, through openFDA) for the ingredient names ‘mechano growth factor’ and ‘PEG-MGF’ returned no match on 8 October 2026¹². FDA says compounded drugs containing PEG-MGF ‘may pose significant risk for immunogenicity for certain routes of administration’, meaning they may provoke immune reactions, ‘and may have complexities with regard to peptide-related impurities and API characterization’, that is, in confirming what the active ingredient is and what else it contains. It adds that it ‘has not identified any human exposure data on drug products containing PEG-MGF administered via any route of administration’ and ‘lacks important information regarding any safety issues raised by PEG-MGF, including whether it would cause harm if administered to humans’ (page current 22 April 2026)¹¹. A search of FDA’s adverse event database (FAERS, through openFDA) for ‘PEG-MGF’, ‘mechano growth factor’ and ‘MGF’ returned no reports on 8 October 2026⁴¹. Reporting is voluntary, so that does not show that no harm has occurred. FDA’s substance registry lists the peptide without PEG as MECHANO GROWTH FACTOR, with the identifier UNII Q86M4KXC2P²⁷; that is a naming record, not an approval. In October 2020 a Kentucky compounding pharmacy, Tailor Made Compounding, pleaded guilty to distributing unapproved new drugs from 25 October 2018 to 1 April 2020; according to the plea agreement, the unapproved drugs it distributed included PEG-MGF, along with BPC 157, LL-37, MK 677 and others⁴²⁵⁶. In February 2021 the pharmacy was sentenced to three years of probation and forfeited $1,788,906.82, its 2019 sales of these products⁴².

US pharmacies

Under section 503A, pharmacies may compound only with bulk ingredients that have a USP or NF monograph, are part of an FDA-approved drug or are on FDA’s 503A bulks list⁴⁶. FDA sorts the substances nominated for that list into three categories: under evaluation (Category 1), raising significant safety concerns (Category 2) and nominated without adequate support (Category 3)¹³. PEG-MGF is in none of them as of FDA’s update of 14 May 2026¹³. Wells Pharmacy Network’s nomination of PEG-MGF was received on 23 March 2021²⁶, and FDA’s update of 29 September 2023 added ‘Mechano Growth Factor, Pegylated (PEG-MGF)’ to Category 2⁴³. On 14 April 2026 Wells withdrew its nominations of 12 peptides, PEG-MGF among them⁴⁴. FDA now lists PEG-MGF under ‘Bulk drug substances nominated but withdrawn’, substances ‘previously in category 2’ (page current 22 April 2026)¹¹. HHS Secretary Robert F. Kennedy Jr.’s post of 15 April 2026 on the 12 peptides leaving Category 2 listed ibutamoren mesylate rather than PEG-MGF⁴⁵, but the withdrawal letter and FDA’s page both name PEG-MGF¹¹⁴⁴. A law firm that reported the April 2026 change stressed that removal from Category 2 ‘does not render these bulk drug substances eligible for compounding under section 503A’, and that they stay outside FDA’s interim enforcement discretion policy, ‘which currently extends only to substances in Category 1’¹⁴. MGF without PEG, listed as ‘Mechano growth factor (MGF)’, has been in Category 3 since the 29 September 2023 update and is still there on the list updated 14 May 2026¹³⁴³. FDA says Category 3 substances ‘are not eligible for the policy that applies to substances in category 1’ and that it ‘would consider taking action against a compounder’ using them⁴⁶. PEG-MGF was not on the agenda of the Pharmacy Compounding Advisory Committee meeting of 23 July 2026 and 24 July 2026¹⁵⁵⁴. FDA says the committee will discuss PEG-MGF, with GHK-Cu, LL-37, dihexa acetate and melanotan II, at a meeting before the end of February 2027, listing them as substances ‘being considered for inclusion on the 503A bulks list’⁵³. Two law firms reported the same plan on 16 April 2026 and 27 July 2026¹⁴¹⁵. The committee’s advice is not binding, and FDA must still go through formal rulemaking before adding any substance to the list¹⁴. On 8 October 2026 FDA’s page for the meeting still said its time and place ‘will be scheduled in the coming months’, and a Federal Register search that day found no notice of the meeting, which FDA says it intends to publish⁴⁷⁵³. Neither PEG-MGF nor MGF is on FDA’s 503B list for outsourcing facilities, updated 21 March 2025⁴⁸.

Other countries

Australia: the Poisons Standard in force from 1 October 2026 does not name PEG-MGF or MGF. It lists ‘INSULIN-LIKE GROWTH FACTORS’ as prescription-only (Schedule 4) and in Appendix D clause 5, which covers poisons that must not be possessed without authority, such as a prescription⁴⁰. Whether that group entry covers MGF or PEG-MGF was not verified. Anti-doping scientists wrote in 2012 that MGF ‘has not yet been approved for therapeutic use’²⁰. We found no approval of PEG-MGF as a medicine: FDA’s approval database has no match¹², and FDA says it has not identified any human exposure data on drug products containing PEG-MGF¹¹. Its status in the UK, the EU and Canada was not verified.

Sport

Prohibited at all times, in and out of competition. Class S2.3 of the 2026 Prohibited List names ‘Mechano growth factors (MGFs)’, next to ‘Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues’, and class S2 also covers ‘other substances with similar chemical structure or similar biological effect(s)’¹⁶. The List does not name PEG-MGF separately; because PEG-MGF is sold as MGF with PEG attached, we read the ‘Mechano growth factors (MGFs)’ entry as covering it¹⁶¹⁶. All substances in class S2 are non-Specified, meaning they are not among those WADA considers more likely to be taken for reasons other than sport performance¹⁶. The 2027 List, in force from 1 January 2027, keeps the same entry³⁹. Anti-doping scientists say MGF has been considered prohibited since 2005²¹, and a urine test published in 2024, which its authors validated as an initial testing procedure in doping control, covers ‘human MGF’ and ‘MGF-Goldspink’⁴⁹.

PEG-MGF in the legal tracker →

Quality and the gray market

What testing finds

We found no published independent purity test of PEG-MGF. As of 8 October 2026, Finnrick, an independent testing service that publishes laboratory results for gray-market peptides, listed no published PEG-MGF tests and no rated vendors¹⁷. Seller claims cannot be checked: one claims purity of at least 99%⁶, and another claims ‘98% + Purity’⁷. The only published analysis of a product sold as PEG-MGF that we found is a 2017 chemistry-methods paper: it used ‘PEG MGF’ bought from a research-peptide seller as test material and reported that ‘Non-PEGylated MGF cations can be observed’, that is, MGF without PEG attached; it did not test purity or report whether any PEG-bound peptide was present⁵¹. Anti-doping laboratories have found altered MGF peptides, without PEG, in black-market and seized products. In 2012 both of two black-market preparations were ‘C-terminal amidated analogues of human MGF’, with the end of the chain chemically modified²⁰; a 2017 study found an ‘R23H’ variant in confiscated vials¹⁹; and in 2014 a ‘full-length MGF’ offered to athletes turned out to be a protein closely related to IGF-1Ec, with its last amino acid removed and an arginine replaced by histidine²¹.

How it is sold

PEG-MGF is sold online as powder in 2 mg or 5 mg vials labeled for research use only⁶⁷⁵². On 8 October 2026 one seller listed a 2 mg vial at $40.00 and another at a ‘special price’ of $39.96 against a ‘regular price’ of $49.95⁶⁷. The same day, one research-peptide shop’s popularity-sorted list ranked its 5 mg PEG-MGF 38th of 104 products, at $63.00, ahead of plain MGF (70th, at $50.00) and a product labeled ‘MGF IGF-1 EC’ (104th, at $145.00); the shop says its products ‘are not for human consumption’⁵². Sellers’ pages claim that PEG-MGF ‘directly assists with the up-regulation of protein synthesis and nitrogen retention’ and that it ‘has been investigated in preclinical models’⁶⁷, although we found no published study of PEG-MGF itself⁴⁵. One manufacturer’s page lists ‘INDICATIONS’ including tendon, ligament and muscle repair, muscle wasting, stroke and heart attack, and gives absorption figures ‘in healthy male and female adults’ without naming any study¹⁸; FDA says it has identified no human exposure data for PEG-MGF¹¹.

Side effects and risks

• Unknown human safety. We found no study that gave PEG-MGF to people, and FDA says it lacks information on ‘whether it would cause harm if administered to humans’⁴⁵¹¹.
• Immune reactions and impurities. FDA warns that compounded PEG-MGF may provoke immune reactions with some routes of use and may carry peptide-related impurities¹¹.
• Theoretical cancer concern. A 2026 medical review lists a ‘Theoretical proliferative concern’, a possible push toward cell growth, based on preclinical research on MGF’s natural form in cancer¹. We found no study of PEG-MGF’s long-term safety in animals or people⁴⁵.
• Unknown product content. Finnrick, an independent testing service, had published no tests of PEG-MGF as of 8 October 2026, and anti-doping laboratories have found altered MGF peptides in black-market and seized products^17192021.
• Anti-doping. Mechano growth factors are banned at all times under WADA class S2.3, and anti-doping scientists have published a validated urine test that covers MGF¹⁶⁴⁹.
• Legal. US pharmacies have no lawful route under section 503A to compound PEG-MGF, and a Kentucky compounding pharmacy that distributed it, among other unapproved drugs, was sentenced in 2021¹³¹⁴⁴².

Questions people ask

What is still unknown

• Whether PEG-MGF does anything in people or animals. We found no published study of it.
• What gray-market PEG-MGF vials contain: which peptide sequence, how large a PEG chain, where it is attached and how much of the peptide carries PEG. Finnrick, an independent testing service, had published no tests of PEG-MGF as of 8 October 2026.
• Whether the body makes a free MGF peptide at all. A 2010 review found none identified in cells, tissues or body fluids.
• How long PEG-MGF lasts in the body. Sellers’ claims range from hours to several days, and we found no study that measured it.
• When FDA’s compounding advisers will meet on PEG-MGF, and what FDA will then decide. FDA has said only that the meeting will be before the end of February 2027, and had set no date by 8 October 2026.
• Why sellers and three mouse heart studies use an MGF sequence ending in EEHK, when the human sequence, in both FDA’s substance registry and UniProt, ends in EERK.
• Whether the Australian Poisons Standard’s group entry for insulin-like growth factors covers MGF or PEG-MGF.
• PEG-MGF’s legal status in the UK, the EU and Canada.

Sources

1. 1The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Frontiers in Endocrinology, 18 Jun 2026. frontiersin.org
2. 2Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration Endocrinology, Mar 2010. pubmed.ncbi.nlm.nih.gov
3. 3Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation The Journal of Physiology, 15 Apr 1999. pmc.ncbi.nlm.nih.gov
4. 4PubMed search: PEG or pegylated with mechano growth factor, MGF, IGF-1Ec or E peptide in titles and abstracts (10 results; none tested PEG-MGF itself) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
5. 5PubMed search: ‘PEG-MGF’, ‘pegylated mechano growth factor’ and spelling variants (7 results; only a 2026 review discusses PEG-MGF) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
6. 6PEG-MGF Peptide (Pegylated Mechano Growth Factor) — 2mg Luxe Peptides (vendor), accessed 8 Oct 2026. luxepeptides.is (seller page, deliberately not linked)
7. 7MGF PEG (Pegylated Mechano Growth Factor) US Peptides (vendor), accessed 8 Oct 2026. uspeptides.com (seller page, deliberately not linked)
8. 8Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits International Orthopaedics, Jul 2011. pubmed.ncbi.nlm.nih.gov
9. 9The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction Molecular and Cellular Biochemistry, Sep 2013. pmc.ncbi.nlm.nih.gov
10. 10Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells American Journal of Physiology: Endocrinology and Metabolism, 15 Jan 2014. pubmed.ncbi.nlm.nih.gov
11. 11Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
12. 12Drugs@FDA via openFDA: search for active ingredients mechano growth factor and PEG-MGF (no matches) U.S. Food and Drug Administration (openFDA), accessed 8 Oct 2026. api.fda.gov · data query
13. 13Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
14. 14FDA to Remove 12 Popular Peptides from the Category 2 ‘Do Not Compound’ List Frier Levitt, 16 Apr 2026. frierlevitt.com
15. 15Bulk-list bound? PCAC backs majority of peptides in two-day public meeting McDermott Will & Schulte, 27 Jul 2026. mcdermottlaw.com
16. 16World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
17. 17PEG-MGF: safety testing results and vendor ratings (no published tests) Finnrick, accessed 8 Oct 2026. finnrick.com
18. 18PEG-MGF - Pegylated Mechano Growth Factor 2mg Cooper Pharma (vendor), accessed 8 Oct 2026. cooperpharma.com (seller page, deliberately not linked)
19. 19Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H Drug Testing and Analysis, Oct 2017. pubmed.ncbi.nlm.nih.gov
20. 20Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products Rapid Communications in Mass Spectrometry, 30 Mar 2012. pubmed.ncbi.nlm.nih.gov
21. 21Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls Growth Hormone & IGF Research, Dec 2014. pubmed.ncbi.nlm.nih.gov
22. 22Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction Heart, Lung and Circulation, Feb 2008. pubmed.ncbi.nlm.nih.gov
23. 23An alternatively spliced human insulin-like growth factor-I transcript with hepatic tissue expression that diverts away from the mitogenic IBE1 peptide Endocrinology, May 1995. pubmed.ncbi.nlm.nih.gov
24. 24Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch Journal of Muscle Research and Cell Motility, Aug 1996. pubmed.ncbi.nlm.nih.gov
25. 25Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation FEBS Letters, 3 Jul 2002. pubmed.ncbi.nlm.nih.gov
26. 26Nomination from Wells Pharmacy Network (FDA-2015-N-3534-0292) Regulations.gov (U.S. Food and Drug Administration docket FDA-2015-N-3534), 1 Apr 2021. regulations.gov
27. 27MECHANO GROWTH FACTOR (UNII Q86M4KXC2P) substance record FDA Global Substance Registration System (GSRS), accessed 8 Oct 2026. precision.fda.gov
28. 28Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction Biomaterials, Apr 2015. pmc.ncbi.nlm.nih.gov
29. 29Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction International Journal of Cardiovascular Research, 24 Jun 2014. pmc.ncbi.nlm.nih.gov
30. 30ClinicalTrials.gov search: PEG-MGF, ‘mechano growth factor’, ‘mechano-growth factor’ or IGF-1Ec (501 records; none gave MGF or PEG-MGF, two measure the body’s own MGF) ClinicalTrials.gov, accessed 8 Oct 2026. clinicaltrials.gov
31. 31PubMed search: mechano growth factor or MGF in titles and abstracts, limited to clinical trials (21 results; none gave people an MGF peptide) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
32. 32Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles Journal of Pharmaceutics, 2013. pmc.ncbi.nlm.nih.gov
33. 33First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I Growth Hormone & IGF Research, Apr 2017. pubmed.ncbi.nlm.nih.gov
34. 34A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success American Journal of Transplantation, Oct 2007. pubmed.ncbi.nlm.nih.gov
35. 35Mechano-growth factor E peptide promotes healing of rat injured tendon Biotechnology Letters, Oct 2016. pubmed.ncbi.nlm.nih.gov
36. 36A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia FASEB Journal, Nov 2005. pubmed.ncbi.nlm.nih.gov
37. 37Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection Frontiers in Physiology, 2019. pmc.ncbi.nlm.nih.gov
38. 38Editorial: the fall of mechanogrowth factor? Molecular Endocrinology, Feb 2014. pmc.ncbi.nlm.nih.gov
39. 39World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
40. 40Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
41. 41FDA Adverse Event Reporting System (FAERS) reports naming PEG-MGF, mechano growth factor or MGF, retrieved via the openFDA drug/event API (no matches) U.S. Food and Drug Administration (openFDA), accessed 8 Oct 2026. api.fda.gov · data query
42. 42Nicholasville Compounding Pharmacy and Its Owner Sentenced for Unlawful Distribution of Prescription Drugs U.S. Attorney’s Office, Eastern District of Kentucky, 24 Feb 2021. justice.gov
43. 43Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list updated 29 September 2023) U.S. Food and Drug Administration (copy hosted by the Alliance for Pharmacy Compounding), 29 Sep 2023. join.a4pc.org
44. 44Withdrawal from Wells Pharmacy Network (FDA-2015-N-3534-0484) Regulations.gov (U.S. Food and Drug Administration docket FDA-2015-N-3534), 14 Apr 2026. regulations.gov
45. 45X post by HHS Secretary Robert F. Kennedy Jr. (@SecKennedy) on peptides removed from Category 2 X (formerly Twitter), 15 Apr 2026. x.com
46. 46Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov
47. 47Federal Register search: FDA documents mentioning “Pharmacy Compounding Advisory Committee” published since 1 April 2026 Federal Register, accessed 8 Oct 2026. federalregister.gov
48. 48Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 21 Mar 2025. fda.gov
49. 49Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples Journal of Mass Spectrometry, Jan 2024. pubmed.ncbi.nlm.nih.gov
50. 50PEG MGF (2 mg Vial) Dosage Protocol PeptideDosages, 20 Sep 2026. peptidedosages.com
51. 51The Generation of Dehydroalanine Residues in Protonated Polypeptides: Ion/Ion Reactions for Introducing Selective Cleavages Journal of the American Society for Mass Spectrometry, Sep 2017. pmc.ncbi.nlm.nih.gov
52. 52Core Peptides shop page sorted by popularity Core Peptides (vendor), accessed 8 Oct 2026. corepeptides.com (seller page, deliberately not linked)
53. 53Meeting of the Pharmacy Compounding Advisory Committee (to be held before the end of February 2027) U.S. Food and Drug Administration, 15 Apr 2026. fda.gov
54. 54July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
55. 55IGF1_HUMAN (P05019): Insulin-like growth factor 1 UniProt Consortium, 2 Sep 2026. uniprot.org
56. 56Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs U.S. Attorney’s Office, Eastern District of Kentucky, 29 Oct 2020. justice.gov